We are live on ! Find out more
DA

DCF Advisers Portfolio holdings

AUM $375M
1-Year Est. Return 72.65%
This Fund
S&P 500
This Quarter Est. Return
+14.91%
1 Year Est. Return
+72.65%
3 Year Est. Return
+156.29%
5 Year Est. Return
+218.72%
10 Year Est. Return
–
AUM
$242M
AUM Growth
+$46.8M
Cap. Flow
+$26.1M
Cap. Flow %
10.78%
Top 10 Hldgs %
46.63%
Holding
110
New
24
Increased
21
Reduced
24
Closed
20

Top Buys

Rank Stock Value
1
BDX icon
Becton Dickinson
BDX
+$2.39M
2
BABA icon
Alibaba
BABA
+$1.94M
3
GILD icon
Gilead Sciences
GILD
+$1.72M
4
ABBV icon
AbbVie
ABBV
+$1.63M
5
KWEB icon
KraneShares CSI China Internet ETF
KWEB
+$1.48M

Top Sells

Rank Stock Value
1
GOOG icon
Alphabet (Google) Class C
GOOG
+$1.43M
2
IBB icon
iShares Biotechnology ETF
IBB
+$1.35M
3
CSCO icon
Cisco
CSCO
+$1.18M
4
VZ icon
Verizon
VZ
+$1.14M
5
XLNX
Xilinx Inc
XLNX
+$1.04M

Sector Composition

Rank Sector Weight
1 Healthcare 32.28%
2 Technology 13.29%
3 Communication Services 7.57%
4 Financials 4.7%
5 Consumer Discretionary 2.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VZ icon
26
Verizon
VZ
$195B
$2.63M 1.08%
44,750
-19,250
-30% -$1.14M
ALNY icon
27
Alnylam Pharmaceuticals
ALNY
$27.5B
$2.6M 1.07%
20,000
-7,500
-27% -$1M
AMGN icon
28
Amgen
AMGN
$208B
$2.59M 1.07%
11,250
– –
AOD
29
abrdn Total Dynamic Dividend Fund
AOD
$1.11B
$2.54M 1.05%
286,417
– –
BDX icon
30
Becton Dickinson
BDX
$45.6B
$2.5M 1.03%
+10,250
New +$2.39M
BMY icon
31
Bristol-Myers Squibb
BMY
$133B
$2.48M 1.02%
40,000
-1,500
-4% -$92.2K
INTC icon
32
Intel
INTC
$455B
$2.44M 1.01%
49,000
+26,500
+118% +$1.29M
ALXN
33
DELISTED
Alexion Pharmaceuticals
ALXN
$2.34M 0.97%
15,000
+2,000
+15% +$257K
SGEN
34
DELISTED
Seagen Inc. Common Stock
SGEN
$2.33M 0.96%
13,300
+300
+2% +$55.9K
GM icon
35
General Motors
GM
$80.4B
$2.29M 0.94%
55,000
+30,000
+120% +$1.17M
XLNX
36
DELISTED
Xilinx Inc
XLNX
$1.67M 0.69%
11,750
-8,000
-41% -$1.04M
GILD icon
37
Gilead Sciences
GILD
$162B
$1.66M 0.68%
+28,500
New +$1.72M
BABA icon
38
Alibaba
BABA
$293B
$1.63M 0.67%
+7,000
New +$1.94M
JNJ icon
39
CALL
Johnson & Johnson
JNJ
$618B
$1.57M 0.65%
+10,000
New +$1.48M
MS icon
40
Morgan Stanley
MS
$331B
$1.54M 0.64%
+22,500
New +$1.29M
STEW
41
SRH Total Return Fund
STEW
$1.79B
$1.3M 0.54%
116,593
+3,800
+3% +$40K
LOW icon
42
Lowe's Companies
LOW
$117B
$1.2M 0.5%
7,500
– –
KYNB
43
Kyntra Bio
KYNB
$27.2M
$1.15M 0.47%
1,240
+280
+29% +$294K
LNSR icon
44
LENSAR
LNSR
$61.5M
$1.14M 0.47%
+157,250
New +$1.35M
NOK icon
45
Nokia
NOK
$51B
$1.13M 0.47%
290,000
+30,000
+12% +$118K
LLY icon
46
Eli Lilly
LLY
$1.02T
$1.01M 0.42%
+6,000
New +$896K
ESPR
47
DELISTED
Esperion Therapeutics
ESPR
$1M 0.41%
38,500
-18,000
-32% -$539K
APTV icon
48
Aptiv
APTV
$12B
$977K 0.4%
7,500
– –
TDC icon
49
Teradata
TDC
$2.92B
$955K 0.39%
+42,500
New +$912K
AMRN
50
Amarin Corp
AMRN
$298M
$929K 0.38%
9,500
-2,988
-24% -$288K
1
2
3 4 5

Similar funds

JIC
JRM Investment Counsel Omaha, Nebraska $375M AUM 13.43% 1-Year Est. Return
CIM
CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return
AIM
Access Investment Management Atlanta, Georgia $376M AUM 17.2% 1-Year Est. Return
MWM
McMill Wealth Management Norfolk, Nebraska $376M AUM 14.46% 1-Year Est. Return
RCP
RIT Capital Partners London, United Kingdom $374M AUM 25.18% 1-Year Est. Return
HPM
Helix Partners Management New York $374M AUM 136.73% 1-Year Est. Return
CAG
Compass Advisory Group Melville, New York $374M AUM 14.59% 1-Year Est. Return
LWMNY
Landmark Wealth Management (New York) Melville, New York $373M AUM 12.01% 1-Year Est. Return

DCF Advisers's Q4 2020 Portfolio in Review

As of Q4 2020, DCF Advisers held 110 positions worth $242M, up 24% from $196M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

DCF Advisers deployed $26.1M of net new capital in Q4 2020, opening 24 new positions and adding to 21 existing holdings. Its largest new stake was Becton Dickinson: 10,250 shares worth $2.5M.

By sector, the portfolio is most concentrated in Healthcare at 32% of assets, down from 35% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Alphabet (Google) Class C, an estimated $1.43M trimmed.

  • DCF Advisers's largest Q4 2020 buy was Becton Dickinson: 10,250 shares worth $2.5M.
  • DCF Advisers added most to AbbVie in Q4 2020, an estimated $1.63M increase.
  • DCF Advisers's biggest Q4 2020 reduction was Alphabet (Google) Class C, cutting an estimated $1.43M.
  • DCF Advisers fully exited iShares Biotechnology ETF in Q4 2020, selling an estimated $1.35M.
  • DCF Advisers's ten largest holdings make up 47% of its $242M portfolio in Q4 2020.
  • DCF Advisers opened 24 new positions and closed 20 in Q4 2020.
  • DCF Advisers's portfolio value rose 24% quarter-over-quarter to $242M.

Based on DCF Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.